Disclosures: Loghman Salimzadeh: Nothing to Disclose, Stuti Shah: Nothing to Disclose, Danie La: Nothing to Disclose, Hilario Ramos: Bluejay Therapeutics: Employee, Bluejay Therapeutics: Stock privately held company, Nancy Shulman: Bluejay Therapeutics, INC: Salary and equity, Hassan Javanbakht: Nothing to Disclose, Adam Gehring: Nothing to Disclose 452 PRECLINICAL PHARMACOKINETICS OF EDP-514, AN ORAL, ONCE-DAILY ANTIVIRAL TREATMENT FOR HEPATITIS B VIRUS Meng Huang 1 Khanh Hoang 1 Jonathan Kibel 1 Shucha Zhang 1 Lisha Xu 1 Yang Li 1 Indy Zang 1 Daniel Leonard 1 Siu-Lung Chan 1 Joshua Klaene 1 Yat Sun Or 1 Li-Juan Jiang 1 , 1 Enanta Pharmaceuticals Background: Hepatitis B virus (HBV) is a global public health threat that causes approximately 1.5 million new infections every year
Placebo condition was removed, as THC concentrations were steady, as expected, during the placebo sessions
Para quin est indicado GLP-1 Metabolic
Ordering and Application: The company says you can order through their website, tryozempatch.com, and you will get tracking information
